Form 4: Scholar Rock CHRO Sells Shares for Tax Obligations

Scholar Rock Holding Corp's CHRO, Caryn Parlavecchio, sold 9,035 shares of common stock at $46.5282 to cover tax withholding obligations related to RSU vesting.

Summary

• Caryn Parlavecchio, Chief Human Resources Officer (CHRO) of Scholar Rock Holding Corp (SRRK), reported a transaction involving the company's common stock.
• A total of 9,035 shares of common stock were sold on February 17, 2026, at a price of $46.5282 per share.
• The sale was a non-discretionary 'sell to cover' transaction, executed to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs).
• This transaction was mandated by the Issuer's equity incentive plans, requiring the reporting person to fund tax obligations through a designated brokerage firm.
• The RSUs that triggered this sale vested on February 15, 2026, and were part of awards granted on February 13, 2023, and March 10, 2025.
• Following the transaction, Ms. Parlavecchio beneficially owns 169,087 securities, comprising 86,859 shares of common stock and 82,228 unvested RSUs.
• The RSU awards typically vest annually over four years, contingent upon continued service with the Issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, non-discretionary transaction for tax purposes related to equity compensation, rather than a discretionary sale indicating a change in management's outlook.

Negatives

• The transaction resulted in a reduction of 9,035 shares of common stock held by a key executive, though it was a non-discretionary sale for tax purposes.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are standard practice for executives receiving equity compensation, particularly Restricted Stock Units (RSUs). This type of transaction is common across the biotechnology and pharmaceutical sectors, where equity-based compensation is a significant component of executive pay, aligning management incentives with shareholder value.

Comparison to Industry Standards

• This 'sell to cover' transaction aligns with common practices observed in the biotechnology industry for executive equity compensation.
• Companies like Moderna (MRNA) and BioNTech (BNTX) frequently see similar non-discretionary sales by executives to manage tax liabilities upon RSU vesting, reflecting standard compensation and tax planning mechanisms rather than a discretionary investment decision.

Related Party Transactions

• The sale of shares by CHRO Caryn Parlavecchio to cover tax obligations related to RSU vesting is a standard related-party transaction within the scope of executive compensation plans.

Stakeholder Impact

• Shareholders: The transaction is a routine, non-discretionary event and is unlikely to significantly impact shareholder sentiment or the company's valuation.
• Employees: Reflects standard equity compensation practices for executives, which are common across the industry.

Key Dates

Recommendation

The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, not a discretionary sale. It does not indicate a change in the insider's confidence or the company's fundamentals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Scholar Rock Holding Corp, SRRK, Caryn Parlavecchio, CHRO, Insider Transaction, Form 4, Restricted Stock Units, RSU, Sell to Cover, Tax Withholding, Equity Compensation